Maridebart Cafraglutide
An experimental once-monthly shot from Amgen that switches on GLP-1 and blocks the GIP receptor.
- Evidence
- Ongoing clinical research
- Half-life
- Weeks
- Sources
- 2 cited
Is maridebart Cafraglutide FDA-approved?
Investigational. Not FDA-approved.
Overview
MariTide links two GLP-1 peptides to an antibody that blocks the GIP receptor, which lets it last about a month. In a 52-week phase 2 trial, adults with obesity lost about 12–16% of body weight on average, versus about 2.5% on placebo. Phase 3 trials are underway.
How it works
The GLP-1 part reduces appetite and helps insulin. Blocking (rather than switching on) GIP also led to weight loss in genetic and animal studies, and the antibody backbone keeps the drug in the body for weeks.
How long does maridebart Cafraglutide stay in the body?
Weeks rather than days, which supports once-monthly shots.
What it's studied for
- Obesity
- Type 2 diabetes
- Monthly dosing
Reported side effects
- Nausea and vomiting, mostly after the first dose
Related: Amycretin, Petrelintide, Orforglipron, Eloralintide.
Sources
The studies and prescribing labels this page is written from.
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity: A Phase 2 Trial. N Engl J Med, 2025 PubMed
- A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss in preclinical and phase 1 settings. Nat Metab, 2024 PubMed
